Ofatumumab, a fully humanized anti-CD20 monoclonal antibody, is the only highly effective disease modifying therapy (DMT) approved for the treatment of relapsing multiple sclerosis (RMS) in China up to data. Real-world data are necessary to investigate the factors for switching from oral DMTs and to assess the effectiveness and safety of ofatumumab in the Chinese MS population. We conducted a...
Most of the patients with multiple sclerosis (MS) suffer from cognitive impairment, fatigue and/or mood disturbances. These symptoms are usually resistant to both disease-modifying and symptomatic treatment. Since there is a trend to a holistic approach to MS patients, we aimed to confirm the effect of combined cold exposure, controlled breathing and mindfulness - Wim Hof Method (WHM) - on...
Therapeutics of neuroinflammatory disorders including multiple sclerosis is one of the fastest growing areas in neurology. However, pressures on higher specialty training in neurology together with an expanding curriculum have led to challenges in adequately preparing trainees for a subspecialist career. In this study we set out to understand current perceptions and barriers to training in...